Sangamo Enters License Agreement With Genentech To Develop Intravenously Administered Genomic Medicines For Neurodegenerative Diseases; Co. Expected To Receive $50M In Near-Term Upfront License Fees And Is Eligible For Up To $1.9B In Milestones
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for neurodegenerative diseases. Sangamo will receive $50 million in upfront license fees and is eligible for up to $1.9 billion in milestone payments.
August 06, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics has entered into a significant license agreement with Genentech, which includes $50 million in upfront fees and potential milestone payments up to $1.9 billion. This partnership aims to develop genomic medicines for neurodegenerative diseases.
The partnership with Genentech provides Sangamo with immediate financial benefits and significant future revenue potential. The focus on neurodegenerative diseases could also enhance Sangamo's market position in the biotech sector.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100